mardi 23 janvier 2018

Onco Actu du 23 janvier 2018

2. Etiologie

EFSA confirms health concerns for hydroxyanthracene derivatives in food [EFSA]

Europe's safety watchdog says laxatives may increase cancer risk [Reuters]

4.1 Dép., diag. & prono. - Prostate

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer [Myriad]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

NICE Develops a Medtech Innovation Briefing on the MammaTyper In Vitro Diagnostic Test [ESMO]

4.12 Biopsies liquides

A Hard Look At Liquid Biopsies [In the Pipeline]

5.1 Traitements - Pré-clinique

Combination chemotherapy may significantly improve treatment for deadly brain tumor [Mass. General Hospital]

WATCH: How origami could help treat cancer [STAT]

5.10 Traitements - Essais

NCI CTEP-Approved Trials for January [The Cancer Letter]

How well can you predict the outcome of clinical trials? Not as well as you may think [STAT]

5.12.10 Immunothérapies - Fusions et acquisitions

Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 [FierceBiotech]

Bluebird Bio Shouldn't Be Blue [Bloomberg]

Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy [Celgene]

Celgene bags CAR-T player Juno in $9B buyout as biotech M&A suddenly explodes [EndPoints]

5.12.2 Immunothérapies - CAR-T

A unique drug for each patient: a paradigm shift in cancer therapy [The Cancer Letter]

5.12.5 Immunothérapies - Pharma

Eureka nets $60M to take T-cell therapy into the clinic [FierceBiotech]

Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy [Xconomy]

5.12.6 Immunothérapies - AMM

European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma [BMS]

5.2 Pharma

Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia [Astellas]

Genmab Announces Novartis' Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets [Genmab]

5.3 Traitements - FDA, EMA, NICE...

Human medicines highlights 2017 [EMA]

5.3.4 Traitements - AMM (FDA, EMA,...)

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy – Providing an Innovative Treatment Option to Patients [Takeda]

6.6 Publications

Online tool calculates reproducibility scores of PubMed papers [Science]